News Breaks |
|
|
| September 7, 2012 |
| 07:32 EDT |  | MYL, PFE | Mylan settles with Pfizer over generic Detrol LA
Mylan (MYL) announced that it and its subsidiary, Mylan Pharmaceuticals, have entered into a settlement agreement with Pfizer (PFE) and related parties that will resolve the parties' patent litigation in connection with Mylan Pharmaceuticals' Abbreviated New Drug Application for Tolterodine Tartrate ER capsules, 2 mg and 4 mg, which is the generic version of Pfizer's Detrol LA, indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. According to the terms of the settlement agreement, Mylan may begin to sell the product on January 1, 2014, or earlier under certain limited circumstances, and no later than March 1, 2014, subject to final approval from the U.S. Food and Drug Administration. Under the terms of the agreement, Mylan may launch the product as either an authorized generic or under its own ANDA. Pursuant to the agreement, the pending litigation will be dismissed. Other details of the settlement are confidential, and the agreements are subject to review by the Federal Trade Commission and the U.S. Department of Justice. Tolterodine Tartrate ER capsules, 2 mg and 4 mg, had U.S. sales of approximately $599M for the 12 months ending June 31, 2012, according to IMS Health. |
|
|
News For MYL;PFE From The Last 14 Days Check below for free stories on MYL;PFE the last two weeks. |
|
|
| June 18, 2013 |
| 09:38 EDT |  | PFE | Active equity option families trading on open
Active equity option families trading on open according to Track Data: AAPL NFLX GOOG PFE TSLA MGM |
|
| 08:36 EDT |  | MYL | Elan shares could be worh $19 in a buyout, says Jefferies
Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. |
|
| June 17, 2013 |
| 16:00 EDT | | PFE | Options Update; June 17, 2013
 Subscribe for More Information |
|
| 13:20 EDT | | MYL | Supreme Court rules generic drug makers can be sued over 'pay to delay'
Subscribe for More Information |
|
| 11:54 EDT | | MYL | Supreme Court ruling a modest negative for generics, says Leerink
Subscribe for More Information |
|
| 08:36 EDT | | MYL, PFE | InSite Vision to join Merck, Pfizer patent suit against Mylan
InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. |
|
| 07:28 EDT |  | PFE | Cambridge Healthtech Institute to host a conference
Subscribe for More Information |
|
| June 14, 2013 |
| 16:00 EDT | | PFE | Options Update; June 14, 2013
Subscribe for More Information |
|
| 06:45 EDT | | PFE | Zoetis volatility elevated into Pfizer split-off
Subscribe for More Information |
|
| June 13, 2013 |
| 17:23 EDT |  | MYL | Mylan files automatic mixed securities shelf
Subscribe for More Information |
| |
| 16:00 EDT | | PFE | Options Update; June 13, 2013
Subscribe for More Information |
|
| 07:32 EDT | | PFE | European League Against Rheumatism to host annual meeting
Subscribe for More Information |
|
| June 12, 2013 |
| 16:02 EDT | | PFE | Options Update; June 12, 2013
Subscribe for More Information |
|
| 13:47 EDT | | MYL | Mylan sees buying back stock in near future, Bloomberg says
Subscribe for More Information |
|
| 13:31 EDT | | MYL, PFE | Mylan could be interested in generic assets split from Pfizer, Bloomberg says
|
|
| 13:28 EDT | | MYL | Mylan chairman said explored possible Hospira deal Bloomberg says
Subscribe for More Information |
|
| 08:28 EDT | | PFE | Teva to pay $1.6B to settle with Pfizer, Nycomed over generic Protonix
Subscribe for More Information |
|
| 08:02 EDT | | PFE | Pfizer wins $2.15B settlement from Teva and Sun for patent infringement
Subscribe for More Information |
|
| June 11, 2013 |
| 16:00 EDT | | PFE | Options Update; June 11, 2013
Subscribe for More Information |
|
| 15:15 EDT | | PFE | Pfizer June volatility at one-year high
Subscribe for More Information |
| |
|
|
|
|
